Homegrown smartphone firm increasingly targeted by licensors has upped its research output in recent years
A state-run telecom's claim to be producing its own networking gear is the latest indication that there are opportunities for IP-based collaboration in a fast growing tech market
Fractus, a Barcelona-based antenna tech developer, comes up short in its bid to secure a key European injunction against the Chinese mobile maker
There are significant gains for branded pharma in the agreement. But in several other areas, China has made commitments it already meets
The award of $448 million in antitrust damages against the company in case brought by the Federal Trade Commission is also at stake.
Oral hearings before the EPO’s Boards of Appeal may have a big impact on the European Cas9 landscape
Apple top defendant again; Eastern District of Texas loses further ground; and other key stats
Last year patent agencies came under scrutiny for gaming the system, and corporate IP managers say they expect tighter auditing in the year to come
Nineteen companies in all took the chance to secure rights to the portfolio before a contingent of South Korean and Japanese patent owners departed the pool last Thursday
The California case was one of the early patent battles over the breakthrough cancer cell therapy technology, which is set to become a crowded space in years to come.
Arlington-based firm acts for more of the companies that own the biggest US portfolios than any other, with Foley & Lardner and Harness Dickey & Pierce rounding out the top three
Latest data shows Global Foundries, IV and Seiko among top sellers; NPEs the top buyers, with Samsung, Pinterest and BBK Electronics also among the leaders
More than half the companies that make up the IAM/ktMINE listing of the entities with the biggest US portfolios have instructed Fish lawyers to represent them in district court disputes over the course of the last decade
Trump administration said to be considering weakening provisions to break political gridlock over USMCA
Secret government documents detailing pharma patent discussions between UK and US officials have stirred up a controversy in the run up to the British general election later this month